BioSpace News Archive

IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of the Company’s ongoing Phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease.

MyMD Pharmaceuticals, Inc. announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week.

Cardio Diagnostics Holdings, Inc. announced that Australia’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation for Australian Patent Application No. 2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”

Syneos Health, Inc. announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier.

The higher the level of a marker of inflammation in circulating blood, the greater the risk of dying from a range of medical disorders, according to a new study published in PLOS ONE.

CDI Laboratories Inc., the Seromics™ company, announced that Barney E. Saunders Ph.D. has been appointed Chief Executive Officer.

Mirvie announced a $4.6 million grant from the Bill & Melinda Gates Foundation to support the company’s efforts to predict unexpected pregnancy complications before they happen by revealing the underlying biology of each pregnancy for women on a global scale.

Orchard Therapeutics, a global gene therapy leader, expresses its strong appreciation for the passage of the Newborn Metabolic Screening Act in Illinois, also known as SB67.

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: “The second quarter makes evident that the execution against our strategic plan is fully on track.

CDx Diagnostics, Inc., developer of the WATS3D AI Platform for the detection and surveillance of Barrett’s esophagus (BE) and dysplasia, reported positive data in a recently published study, Benefit of Adjunctive Wide Area Transepithelial Sampling with 3- Dimensional Computer-Assisted Analysis Plus Forceps Biopsy Based on Barrett’s Esophagus Segment Length.